Demographic and baseline characteristics of patients
| Characteristic . | Proportion of patients (n = 106) . |
|---|---|
| Sex (male %/female %) | 79.2/20.8 |
| Median age (y) (minimum, maximum) | 62 (37, 73) |
| ≥65 | 30 (28.3) |
| Stage of lymphoma | |
| Stage III | 22 (20.8) |
| Stage IV | 78 (73.6) |
| Total stages III and IV | 100 (94.3) |
| Ki-67-positive cell percentage | |
| <30% | 39 (36.8) |
| ≥30% | 63 (59.4) |
| Missing | 4 (3.8) |
| Blastoid morphology of MCLs | 8 (7.5) |
| Bone marrow exam–positive | 43 (40.6) |
| HBcAb-positive | 55 (52.4) |
| ECOG score | |
| 0 | 49 (46.2) |
| 1 | 53 (50.0) |
| 2 | 4 (3.8) |
| Longest target lesion diameter | |
| ≥5 and <10 cm | 30 (28.3) |
| ≥10 cm | 11 (10.4) |
| MIPI-b | |
| Low risk (0-3) | 54 (50.9) |
| Intermediate risk (4-5) | 31 (29.2) |
| High risk (6-11) | 11 (10.4) |
| Missing | 10 (9.4) |
| With relapsed disease | 30 (28.3) |
| With refractory disease | 32 (30.2) |
| Splenomegaly | 24 (22.6) |
| Hepatomegaly | 12 (11.3) |
| Median prior lines of therapy | 2 (1.4) |
| Received anti-CD20–based therapy | 94 (88.7) |
| Received CHOP | 74 (69.8) |
| Received CVAD or hyper-CVAD | 13 (12.3) |
| Received DHAP | 24 (22.6) |
| Received bortezomib | 13 (12.3) |
| Received lenalidomide | 8 (7.6) |
| Received thalidomide (not lenalidomide) | 16 (15.1) |
| Autologous stem cell transplantation | 8 (7.5) |
| Characteristic . | Proportion of patients (n = 106) . |
|---|---|
| Sex (male %/female %) | 79.2/20.8 |
| Median age (y) (minimum, maximum) | 62 (37, 73) |
| ≥65 | 30 (28.3) |
| Stage of lymphoma | |
| Stage III | 22 (20.8) |
| Stage IV | 78 (73.6) |
| Total stages III and IV | 100 (94.3) |
| Ki-67-positive cell percentage | |
| <30% | 39 (36.8) |
| ≥30% | 63 (59.4) |
| Missing | 4 (3.8) |
| Blastoid morphology of MCLs | 8 (7.5) |
| Bone marrow exam–positive | 43 (40.6) |
| HBcAb-positive | 55 (52.4) |
| ECOG score | |
| 0 | 49 (46.2) |
| 1 | 53 (50.0) |
| 2 | 4 (3.8) |
| Longest target lesion diameter | |
| ≥5 and <10 cm | 30 (28.3) |
| ≥10 cm | 11 (10.4) |
| MIPI-b | |
| Low risk (0-3) | 54 (50.9) |
| Intermediate risk (4-5) | 31 (29.2) |
| High risk (6-11) | 11 (10.4) |
| Missing | 10 (9.4) |
| With relapsed disease | 30 (28.3) |
| With refractory disease | 32 (30.2) |
| Splenomegaly | 24 (22.6) |
| Hepatomegaly | 12 (11.3) |
| Median prior lines of therapy | 2 (1.4) |
| Received anti-CD20–based therapy | 94 (88.7) |
| Received CHOP | 74 (69.8) |
| Received CVAD or hyper-CVAD | 13 (12.3) |
| Received DHAP | 24 (22.6) |
| Received bortezomib | 13 (12.3) |
| Received lenalidomide | 8 (7.6) |
| Received thalidomide (not lenalidomide) | 16 (15.1) |
| Autologous stem cell transplantation | 8 (7.5) |
Data presented as n (%), except as noted.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; ECOG, Eastern Cooperative Oncology Group; HBcAb, hepatitis B core antibody; MIPI-b, MCL international prognostic index combined biologic index.